70724-25-3
70724-25-3
Chemical Structure
Carbazeran
- CAS No.: 70724-25-3
- Formula:C18H24N4O4
- Molecular Weight:360.41
IUPAC Name: 1-(6,7-dimethoxyphthalazin-1-yl)piperidin-4-yl ethylcarbamate
InChIKey: QJGVXJYGDBSPSJ-UHFFFAOYSA-N
SMILES: COC1=CC2=C(C=C1OC)C=NN=C2N3CCC(OC(NCC)=O)CC3
Biological Activity: Carbazeran is a phosphodiesterase inhibitor. Carbazeran is oxidized by aldehyde oxidase/AOX1 to 4-oxo-carbazeran/hydroxycarbazeran, serving as an AOX1 probe and competitively inhibiting xanthine oxidase. Carbazeran can be used in research on congestive heart failure and chronic heart failure[1][2][3][4][5][6][7][8][9].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Carbazeran | 99.94% | Carbazeran is a phosphodiesterase inhibitor. Carbazeran is oxidized by aldehyde oxidase/AOX1 to 4-oxo-carbazeran/hydroxycarbazeran, serving as an AOX1 probe and competitively inhibiting xanthine oxidase. Carbazeran can be used in research on congestive heart failure and chronic heart failure. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Hoey M, et al. Identification and selective inhibition of four distinct soluble forms of cyclic nucleotide phosphodiesterase activity from kidney. Biochemical pharmacology. 1990 Jul 15;40(2):193-202. [Content Brief]
- [2]. Beedham C, et al. 1-substituted phthalazines as probes of the substrate-binding site of mammalian molybdenum hydroxylases. Biochemical pharmacology. 1990 Apr 01;39(7):1213-21.
- [3]. Fu C, et al. Aldehyde oxidase 1 (AOX1) in human liver cytosols: quantitative characterization of AOX1 expression level and activity relationship. Drug metabolism and disposition: the biological fate of chemicals. 2013 Oct;41(10):1797-804. [Content Brief]
- [4]. Manevski N, et al. Aldehyde oxidase activity in fresh human skin. Drug metabolism and disposition: the biological fate of chemicals. 2014 Dec;42(12):2049-57.
- [5]. Kaye B, et al. A species difference in the presystemic metabolism of carbazeran in dog and man. Xenobiotica; the fate of foreign compounds in biological systems. 1984 Dec;14(12):935-45.
- [6]. Kweh JR, et al. Mechanism-based inactivation of human aldehyde oxidase by erlotinib: Mechanistic insights from structural analogs and molecular docking. Molecular pharmacology. 2026 Jan;108(1):100097.
- [7]. Weishaar RE, et al. The effect of several “new and novel” cardiotonic agents on key subcellular processes involved in the regulation of myocardial contractility: implications for mechanism of action. Drug development research. 1983;3(6):517-34.
- [8]. Xie J, et al. Evaluation of Carbazeran 4-Oxidation and -Benzylguanine 8-Oxidation as Catalytic Markers of Human Aldehyde Oxidase: Impact of Cytosolic Contamination of Liver Microsomes. Drug metabolism and disposition: the biological fate of chemicals. 2019 Jan;47(1):26-37.
- [9]. Uehara S, et al. Human Aldehyde Oxidase 1-Mediated Carbazeran Oxidation in Chimeric TK-NOG Mice Transplanted with Human Hepatocytes. Drug metabolism and disposition: the biological fate of chemicals. 2020 Jul;48(7):580-586. [Content Brief]
